Ten people who were born deaf heard sound for the first time after receiving a single injection of gene therapy into the inner ear. The patients, ranging in age from 1.5 to 23.9 years, all carried biallelic mutations in the OTOF gene, the cause of a condition known as DFNB9. Their average pure-tone threshold dropped from 106 decibels to 52 decibels, a shift from profound deafness into the mild-to-moderate hearing range. A separate, larger trial tracking 42 patients for up to 2.5 years reported roughly 90 percent hearing recovery, reinforcing the finding that a one-time procedure can produce durable results across a wide age range.
Why a one-dose gene therapy for DFNB9 deafness matters right now
Cochlear implants have been the standard intervention for children born with severe-to-profound hearing loss tied to OTOF mutations. Those devices bypass damaged hair cells with electrical signals, but they require lifelong hardware maintenance, battery changes, and external processors. Gene therapy offers something fundamentally different: it delivers a functional copy of the otoferlin gene directly into the cochlea, aiming to restore the biological hearing pathway itself. The clinical question is no longer whether this approach works in principle but how well it works across different ages and how long the benefit lasts.
The ten-patient single-arm trial used an Anc80L65 viral capsid to carry the therapeutic gene. All ten participants showed measurable hearing improvement, according to Nature Medicine data. That 100 percent response rate in a small cohort is striking, but the wide spread in outcomes, with post-treatment thresholds ranging across a 30-decibel standard deviation, raises a pointed question: does the age at which a patient receives the injection determine how much functional hearing and speech they ultimately gain?
The youngest participants in the ten-patient cohort were 1.5 years old. No one younger than that was enrolled. Yet the brain’s critical window for language acquisition peaks well before 12 months, and auditory cortex plasticity narrows sharply after the first year of life. If age at injection proves to be the dominant predictor of speech recognition scores, then treating infants before their first birthday could yield language development trajectories far superior to what has been observed so far. That hypothesis has not been tested in a controlled trial, but the biological logic is well established, and it shapes the design of ongoing studies enrolling younger children.
Two trials, 52 patients, and up to 2.5 years of follow-up
The evidence base now spans two distinct clinical programs. The first, the ten-patient trial, enrolled participants ages 1.5 to 23.9 with confirmed DFNB9 and delivered AAV-OTOF via intra-cochlear injection. Pure-tone averages improved from a mean of 106 plus or minus 9 decibels to 52 plus or minus 30 decibels. Every treated ear responded, and most patients moved into ranges compatible with conversational speech, even if some still required assistive devices in noisy environments.
The second program is a multicentre investigation that treated 42 participants ages 0.8 to 32.3 with AAV1-hOTOF across eight centers. Follow-up extended up to 2.5 years, and the investigators reported approximately 90 percent hearing recovery based on auditory brainstem response and behavioral audiometry. The inclusion of a patient as young as 0.8 years old edges closer to the infant window that researchers believe could unlock the strongest language outcomes, although detailed speech and language data for this youngest subgroup remain limited in published reports.
An earlier trial provided foundational safety and dosing data. Investigators screened 425 candidates and enrolled six children to receive AAV1-hOTOF via a round-window delivery approach at doses of 9 × 1011 and 1.5 × 1012 viral genomes. That study established the tolerability profile, surgical workflow, and dose range that informed the larger efficacy-focused trials. No dose-limiting toxicities were reported, and adverse events were generally consistent with middle-ear surgery rather than systemic vector exposure.
On the regulatory side, the FDA has approved OTARMENI, the brand name for lunsotogene parvec-cwha, developed by Regeneron and Decibel Therapeutics. The product is indicated for OTOF-associated hearing loss and delivered by intracochlear infusion, according to prescribing information. The CHORD trial, registered as NCT05788536, is the Regeneron/Decibel study of DB-OTO in children and infants with otoferlin mutations. A separate single-arm trial, NCT05901480, is also active. These registrations confirm that multiple research groups are now pursuing the same therapeutic target with slightly different vectors and delivery methods, accelerating the accumulation of real-world experience.
Open questions on durability, infant dosing, and real-world speech gains
The longest follow-up reported so far is 2.5 years. That is encouraging, but otoferlin gene therapy is intended as a permanent fix. Whether a single injection sustains hearing through adolescence and adulthood is unknown. The viral vector used in these studies does not integrate into the genome; instead, it persists as episomal DNA in cochlear cells. As those cells age or turn over, expression could wane. Long-term registries will be needed to track whether thresholds slowly drift upward over a decade or more and whether booster dosing is feasible or safe.
Dosing in infants raises a second unresolved issue. Very young children have smaller cochlear volumes and different immune profiles than adults. The early safety trial and the larger multicentre study both used fixed vector genome doses rather than weight-based schemes, reflecting the anatomical target rather than systemic exposure. Whether that approach remains optimal for infants under 12 months, whose cochleae are still maturing, is not fully clear. Future protocols may test lower or fractionated doses to balance robust gene expression with minimal inflammation while still fitting within the narrow surgical window when language circuits are most plastic.
The third major question is how restored hearing translates into everyday communication. Audiograms and auditory brainstem responses show that many treated children move into the mild-to-moderate or even near-normal range. But speech perception in noise, classroom performance, and social development depend on more than pure-tone thresholds. Some participants in the published trials had already received cochlear implants, speech therapy, or sign language education before gene therapy, complicating the interpretation of post-treatment language gains. Carefully designed prospective studies that enroll infants before extensive alternative interventions will be critical to define the true ceiling of benefit.
Ethical and access considerations are beginning to surface as well. Cochlear implants are widely available in many health systems, with established reimbursement pathways and decades of outcome data. Gene therapy, by contrast, is a bespoke, high-cost procedure delivered at specialized centers. Families may face difficult choices about whether to pursue an irreversible inner-ear surgery for a one-time treatment or to opt for a more familiar implant with known long-term performance. Policymakers and clinicians will need to ensure that decisions are grounded in transparent data rather than hype, particularly as commercial marketing ramps up around newly approved products.
Despite these uncertainties, the core signal is hard to ignore: for a subset of hereditary deafness caused by OTOF mutations, a single intracochlear infusion can convert profound silence into perceivable sound. The convergence of small, detailed mechanistic trials and larger multicentre cohorts points in the same direction, suggesting that otoferlin gene replacement is both biologically plausible and clinically meaningful. As follow-up extends, age at treatment broadens downward into infancy, and speech outcomes are tracked more rigorously, the field will move from proof-of-concept toward a new standard of care for DFNB9. For now, the ten people who heard for the first time after a single injection stand as early evidence of what precision gene therapy can achieve when the target, vector, and timing align.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
